EIKONIZO THERAPEUTICS
Live / Applied — Statement of use — processing complete, to examiner (as of 10 Jan 2026)
What this means for you
Not registered yet, but its 01 Jun 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90747075
- Mark type
- Stylized text
- Filed
- 01 Jun 2021
- Published for opposition
- 14 May 2024
- Attorney of record
- CHRISTINA M. LICURSI
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical, therapeutic and biopharmaceutical agents for the treatment of neurodegenerative and neurological diseases, namely, amyotrophic lateral sclerosis (ALS), Alzheimer's Disease (AD), and chemotherapy-induced peripheral neuropathy (CIPN), treatments in oncology, namely, chemotherapy-induced peripheral neuropathy (CIPN), treatments in nephrology, namely, autosomal dominant polycyclic kidney disease (ADPKD), and treatments in cardiology, namely, cardiac diseases; pharmaceutical, therapeutic and biopharmaceutical preparations and substances or the treatment of neurodegenerative and neurological diseases, namely, amyotrophic lateral sclerosis (ALS), Alzheimer's Disease (AD), and chemotherapy-induced peripheral neuropathy (CIPN), treatments in oncology, namely, chemotherapy-induced peripheral neuropathy (CIPN), treatments in nephrology, namely, autosomal dominant polycyclic kidney disease (ADPKD), and treatments in cardiology, namely, cardiac diseases; diagnostic agents, preparations, substances and diagnostic materials in the form of preparations for medical purposes; imaging agents for positron emission tomography (PET) imaging for delivery of materials to target sites within the body for diagnostic purposes; imaging agents for positron emission tomography (PET) imaging for use in detecting disease, namely, radio tracers for positron emission tomography (PET) imaging
Owner
- Eikonizo Therapeutics, Inc., Cambridge, MA, US
- Eikonizo Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 10 Jan 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 09 Jan 2026 — USE AMENDMENT FILED
- 09 Jan 2026 — TEAS STATEMENT OF USE RECEIVED
- 14 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Jul 2025 — SOU EXTENSION 2 GRANTED
- 08 Jul 2025 — SOU EXTENSION 2 FILED
- 09 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Apr 2025 — SOU EXTENSION 1 GRANTED
- 09 Jan 2025 — SOU EXTENSION 1 FILED
- 24 Apr 2025 — DIVISIONAL PROCESSING COMPLETE
- 09 Jan 2025 — DIVISIONAL REQUEST RECEIVED
- 09 Jan 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 17 Apr 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 09 Jan 2025 — SOU TEAS EXTENSION RECEIVED